Clinical Trial: A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT03998514) titled 'A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease' on June 21.

Brief Summary: This is a 3 part, randomized, double blind, placebo controlled study evaluating the safety, tolerability, PK, and PD of single and multiple ascending SC doses of CB4211 in healthy non obese subjects and subjects with NAFLD.

Study Type: Interventional

Condition: Nonalcoholic Fatty Liver Disease

Intervention: * Drug: CB4211 Dose 1

Administered by subcutaneous injection

* Drug: CB4211 Dose 2

Administered by subcutaneous injection

* Drug: CB4211 Dose 3

Administered by subcutaneous injection ...